Interleukin-17: Friend or foe in atherosclerosis?

Current Opinion in Lipidology

Volumn 21, Issue 5, 2010, Pages 404-408

  Taleb, Soraya ^a   Tedgui, Alain ^a   Mallat, Ziad ^a,b  

^a INSERM   (France)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

atherosclerosis; interleukin 17; lymphocytes

Indexed keywords

INTERLEUKIN 17; LIPOPROTEIN; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 17A; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ARTHRITIS; ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BACTERIUM; CARDIOVASCULAR DISEASE; CELL LINEAGE; CHRONIC INFLAMMATION; FUNGUS; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH2 CELL; THYMUS; UVEITIS;

ANIMALS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; HUMANS; INTERLEUKIN-17; T-LYMPHOCYTES, HELPER-INDUCER;

FUNGI;

EID: 77957576742     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833dc7f9     Document Type: Review

References (62)

1. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86:515-581.
2. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8:802-815.
3. Mallat Z, Taleb S, Ait-Oufella H, Tedgui A. The role of adaptive T cell immunity in atherosclerosis. J Lipid Res 2009; 50 (Suppl):S364-S369.
4. Mays LE, Chen YH. Maintaining immunological tolerance with Foxp3. Cell Res 2007; 17:904-918.
5. Ait-Oufella H, Salomon BL, Potteaux S, et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006; 12:178-180. (Pubitemid 43214743)
6. Sasaki N, Yamashita T, Takeda M, et al. Oral anti-CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 2009; 120:1996-2005.
7. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4 effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-1132.
8. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009; 9:556-567.
9. Marks BR, Nowyhed HN, Choi JY, et al. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat Immunol 2009; 10:1125-1132.
10. Zhou L, Chong MM, Littman DR. Plasticity of CD4 T cell lineage differentiation. Immunity 2009; 30:646-655.
11. Quintana FJ, Basso AS, Iglesias AH, et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008; 453:65-71.
12. Zhang F, Meng G, Strober W. Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17- producing T cells. Nat Immunol 2008; 9:1297-1306.
13. Chen Z, Laurence A, OShea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007; 19:400-408.
14. Das J, Ren G, Zhang L, et al. Transforming growth factor beta is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med 2009; 206:2407-2416.
15. Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051-1057.
16. Annunziato F, Cosmi L, Santarlasci V, et al. Phenotypic and functional features of human Th17 cells. J Exp Med 2007; 204:1849-1861.
17. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8:942-949.
18. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9:641-649.
19. Takatori H, Kanno Y, Watford WT, et al. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009; 206:35-41.
20. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008; 28:454-467.
21. Ruddy MJ, Wong GC, Liu XK, et al. Functional cooperation between interleukin- and tumor necrosis factor-alpha is mediated by CCAAT/ enhancerbinding protein family members. J Biol Chem 2004; 279:2559-2567.
22. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888-898.
23. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452:773-776.
24. Atarashi K, Nishimura J, Shima T, et al. ATP drives lamina propria T(H)17 cell differentiation. Nature 2008; 455:808-812.
25. Gaboriau-Routhiau V, Rakotobe S, Lecuyer E, et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell responses. Immunity 2009; 31:677-689.
26. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139:485-498.
27. Ivanov II, Frutos Rde L, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008; 4:337-349.
28. Zhang Z, Clarke TB, Weiser JN. Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 2009; 119:1899-1909.
29. Torchinsky MB, Garaude J, Martin AP, Blander JM. Innate immune recognition of infected apoptotic cells directs T(H)17 cell differentiation. Nature 2009; 458:78-82.
30. Cho JS, Pietras EM, Garcia NC, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 2010; 120:1762-1773.
31. Mucida D, Park Y, Kim G, et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 2007; 317:256-260.
32. Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453:236-240.
33. Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009; 10:1000-1007.
34. OGarra A, Steinman L, Gijbels K. CD4 T-cell subsets in autoimmunity. Curr Opin Immunol 1997; 9:872-883.
35. Jones LS, Rizzo LV, Agarwal RK, et al. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J Immunol 1997; 158:5997-6005.
36. Eriksson U, Kurrer MO, Bingisser R, et al. Lethal autoimmune myocarditis in interferon-gamma receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction. Circulation 2001; 103:18-21.
37. Murphy CA, Langrish CL, Chen Y, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003; 198:1951-1957.
38. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233-240.
39. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8:345-350.
40. Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008; 29:628-636.
41. McGeachy MJ, Bak-Jensen KS, Chen Y, et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell-mediated pathology. Nat Immunol 2007; 8:1390-1397.
42. Luger D, Caspi RR. New perspectives on effector mechanisms in uveitis. Semin Immunopathol 2008; 30:135-143.
43. Ke Y, Liu K, Huang GQ, et al. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009; 182:3183-3190.
44. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM. IL-12- and IL-23- modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008; 205:1535-1541.
45. Luger D, Silver PB, Tang J, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008; 205:799-810.
46. OConnor W Jr, Kamanaka M, Booth CJ, et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009; 10:603-609.
47. Xie JJ, Wang J, Tang TT, et al. The Th17/Treg functional imbalance during atherogenesis in ApoE(-/-) mice. Cytokine 2010; 49:185-193.
48. Smith E, Prasad KM, Butcher M, et al. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010; 121:1746-1755.
49. de Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010; 220:499-508.
50. Taleb S, Romain M, Ramkhelawon B, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med 2009; 206:2067-2077.
51. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-{gamma} are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009; 119: 1424-1432.
52. van Es T, van Puijvelde GH, Ramos OH, et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009; 388:261-265.
53. Erbel C, Chen L, Bea F, et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in ApoE-deficient mice. J Immunol 2009; 183:8167-8175.
54. Taleb S, Tedgui A, Mallat Z. Adaptive T cell immune responses and atherogenesis. Curr Opin Pharmacol 2010; 10:197-202.
55. von Vietinghoff S, Ley K. IL-17A controls IL-17F production and maintains blood neutrophil counts in mice. J Immunol 2009; 183:865-873.
56. Patel DN, King CA, Bailey SR, et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 2007; 282:27229-27238.
57. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009; 119:1424-1432.
58. Schnyder B, Schnyder-Candrian S, Pansky A, et al. IL-17 reduces TNFinduced Rantes and VCAM-1 expression. Cytokine 2005; 31:191-202.
59. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin IIinduced hypertension and vascular dysfunction. Hypertension 2010; 55: 500-507.
60. Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol 2008; 127:89-97.
61. Mangino M, Braund P, Singh R, et al. Association analysis of IL-12B and IL- 23R polymorphisms in myocardial infarction. J Mol Med 2008; 86:99-103.
62. Pei F, Han Y, Zhang X, et al. Association analysis of the IL-17F His161Arg polymorphism in myocardial infarction. Coron Artery Dis 2009; 20:513-517.